Stilla Technologies

Executive Summary

Stilla Technologies, a French biotechnology company founded in 2016, is advancing precision nucleic acid quantification with its next-generation digital PCR (dPCR) platform, the Nio® system. Distinguished by 7-color multiplexing capability, high throughput, and a streamlined workflow, the Nio system enables highly sensitive and specific detection of genetic targets. Stilla targets critical applications in oncology, genetics, and bioprocessing, where accurate quantification is essential for liquid biopsy, rare mutation detection, and viral load monitoring. The company’s technology addresses limitations of traditional qPCR and earlier dPCR methods by offering greater multiplexing and operational efficiency, positioning it as a competitive player in the rapidly growing dPCR market. With the global digital PCR market projected to expand significantly, driven by demand for precision medicine and bioprocess validation, Stilla is well-poised to capture share. The company’s private status and focus on innovation suggest potential for commercialization milestones and strategic partnerships. Key upcoming catalysts include regulatory clearances for clinical use, expansion into North American and Asian markets, and publication of clinical validation studies. While financial details remain undisclosed, Stilla’s differentiated platform and clear application focus support a positive outlook for growth and adoption.

Upcoming Catalysts (preview)

• Q3 2026CE marking or FDA clearance for Nio system in clinical diagnostics70% success
• Q4 2026Strategic partnership with a major diagnostics or pharmaceutical company50% success
• Q2 2026Publication of key validation studies in peer-reviewed journals for oncology applications80% success